Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
about
Pharmacogenomics and cardiovascular diseaseGenetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjectsPersonalized approaches to clopidogrel therapy: are we there yet?Aspirin and clopidogrel alter core temperature and skin blood flow during heat stress.Clinically relevant genetic variations in drug metabolizing enzymes.Functional genomics applied to cardiovascular medicine.Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response: A Meta-analysis of Randomized Controlled Trials.Relative Copy Number Variations of CYP2C19 in South Indian PopulationCurrent genomics in cardiovascular medicineAdenosine A2A receptor agonists with potent antiplatelet activity.Clinical application of high throughput molecular screening techniques for pharmacogenomics.Predicting clopidogrel response using DNA samples linked to an electronic health record.Pharmacogenetic testing: Current Evidence of Clinical Utility.Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adultsPolymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapyPharmacogenetics and human genetic polymorphisms.Nonresponders to clopidogrel: pharmacokinetics and interactions involved.Personalized echocardiography: clinical applications of advanced echocardiography and future directions.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Genetic determinants of response to cardiovascular drugs.Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.Pharmacogenomics of oral antiplatelet drugs.Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors.Characterization of the genetic profile of CYP2C19 in two South African populations.Pharmacogenetics at 50: genomic personalization comes of age.Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.Distribution of ABCB1, CYP3A5, CYP2C19, and P2RY12 gene polymorphisms in a Mexican Mestizos population.
P2860
Q26997380-697E207E-2468-4DF8-92D0-73D04837EA2DQ33704998-DEE047E7-4132-4413-9F21-62D4DFE1414CQ33963651-E6B7A8CF-D85D-4FB5-9DCC-1F4C1D7D4AF1Q34131354-82006195-BC4E-415C-8FAB-682AA83D3689Q34150640-E1DDF003-9D8B-46E2-9394-00912D43B943Q34186272-E6F73186-871F-4B6E-81CA-00149E50E743Q34460548-F8DA68C8-3080-41A5-A1FB-F99748F000E3Q34470624-08D73C92-2CF4-413E-BB2F-5B7AD52875DBQ35032378-8CF9DCDE-CB0C-4932-9763-3B4775B0E4ECQ35110769-996FEE66-0CF2-456A-B7FD-A6B96FA2BBABQ35846595-60430C00-AFB5-4781-ACC2-9E5DE205731FQ35985453-7E645E6A-84E6-4DFB-B429-2ECC81F1C729Q36076189-2C55AB63-0B67-41B5-A455-809BF2010142Q36186424-AE5908E1-12B6-4BE7-A941-6F7550717360Q36371663-70A6F79D-C267-4E94-890C-036BC9C07A93Q36441517-7FC2C40C-7226-4B5D-A899-09AA862FB739Q36753929-F5FE03EA-CC5E-42D7-A3DC-811EF7E3F666Q37151528-2D90ABFD-09C2-4ACF-8C69-660C8E6C598EQ37167282-EF86BD96-0F4B-4780-8116-6CF3B38077B4Q37388236-2C68A919-99C7-4BA0-A007-46F5B2821483Q37735146-B9D07713-9065-4581-A326-5BFA3C2833CEQ37772183-DACCDD96-5CD5-4461-8154-78A6027A1236Q37786622-F679E4D5-C222-497D-A163-4187AAE1DD11Q37818213-F0DBA043-8BEE-4489-AE9A-5913D239E1C9Q37908891-D645AF31-A25D-4FD7-B473-95E14F8F3C62Q37981892-120B1528-247C-40E9-901D-659725BFFA7DQ37989811-9E993986-C833-44E2-89DA-E461F8A81472Q38094070-EC776F9F-4FDA-4980-BAE6-9431F7549FFCQ38195628-55A0DC40-ED20-4ADA-8A54-B6BB2C3650F8Q38532527-5517AF67-783D-4250-BED4-74ADFA0445F3Q39667176-4F287ED2-D72C-4C33-944D-D18FDE4F5307Q40165805-1D1BA2AB-24BC-4E72-8BB8-EB487323AE8EQ42961046-6CD0CB33-5153-44D8-8FD6-2A20A78CBC56Q43121565-6215000A-2064-47A7-AE90-DF211D41DA75Q50940254-C0FFABAF-09E3-4647-B535-B671E777151AQ53833189-5CC0A303-A7EF-42E5-B5A2-D8003CE89131
P2860
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.
@en
Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.
@nl
type
label
Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.
@en
Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.
@nl
prefLabel
Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.
@en
Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.
@nl
P2093
P2860
P356
P1433
P1476
Clopidogrel pharmacogenomics a ...... ition: US FDA recommendations.
@en
P2093
Craig R Lee
George A Stouffer
Howard L McLeod
Kyle J Ellis
P2860
P304
P356
10.2217/PGS.09.143
P577
2009-11-01T00:00:00Z